An Observational Study Evaluating SYMLIN® (pramlintide acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Study identifier:137-161

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Prospective, Open-Label, Observational Study Evaluating SYMLIN® (pramlintide acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes Following SYMLIN Introduction Into the Marketplace

Medical condition

Type 1 Diabetes Mellitus

Phase

-

Healthy volunteers

No

Study drug

pramlintide acetate

Sex

All

Actual Enrollment

1297

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Sept 2005
Primary Completion Date: 01 May 2008
Study Completion Date: 01 May 2008

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria